The authors declare that they have no competing interests.
AO conceptualized and designed the study. MN assembled code lists, performed the validation study, and assisted in data cleaning. KJ wrote the first draft of the manuscript. LT and CW created the analytic datasets and performed the statistical analysis. All authors including JB and NM were integral in interpretation of the results, and all approved the final version of the manuscript.
Rheumatoid arthritis (RA) has been associated with an increased risk of cardiovascular morbidity and mortality but this has not translated to optimal management of traditional cardiovascular risk factors such as hyperlipidemia. The objectives of this study were to 1) determine the prevalence of screening for hyperlipidemia in patients with RA followed by primary care practitioners (PCP); 2) examine initiation of lipid-lowering therapy in patients with an indication, and 3) assess whether proposed modifications to cardiovascular risk calculations change the percentage of RA patients with an indication for therapy.
We performed a retrospective cohort study using an academic medical center-based medical record database in the United States. Patients with RA defined by the presence of at least one ICD-9 code between 2005–2010 and followed by a PCP within the health care system were included. The positive predictive value of ICD-9 codes for accurately identifying patients with RA was 96.7 %. Descriptive statistics were used to report the prevalence of screening and use of lipid-lowering therapy among those with an indication. Factors associated with not receiving lipid screening were examined using logistic regression models. Indication for and receipt of therapy were then assessed before and after the application of the European Union League Against Rheumatism (EULAR) recommended multiplier to the Framingham risk score.
Among 1,056 patients with RA followed by PCPs and eligible for lipid screening, lipid screening was ordered for 539 (51 %) within the 3-year follow-up period. Patients with diabetes, hypertension, chronic kidney disease, obesity or age >50 were more likely to be screened. Of those with lipid results (N = 290), 25 (9 %) patients had an indication for lipid-lowering therapy based on Adult Treatment Panel III guidelines. Ten (40 %) patients with an indication for lipid-lowering therapy received therapy did not receive therapy. Applying the EULAR multiplier only changed the indication for lipid-lowering therapy in two patients.
Screening and management of traditional cardiovascular risk factors, including hyperlipidemia, need to be optimized.
Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a populationbased cohort study. Arth Rheum. 2005;52:402–11. CrossRef
Rasch E, Hirsch R, Paulose-Ram R, Hochberg M. Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arth Rheum. 2003;48(4):917–26. CrossRef
Gazi I, Boumpas D, Mikhailidis D, Ganotakis E. Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins. Clin Exp Rheumatol. 2007;25(1):102–11. PubMed
Symmons D, Gabriel S. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE Nat Rev. Rheumatol. 2011;7:399–408.
Bartels C, Kind A, Everett C, Mell M, McBride P, Smith M. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arth Rheum. 2011;63(5):1221–30. CrossRef
Soubrier M, Zerkak D, Dougados M. Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem. J Rheumatol. 2006;33(9):1766–9. PubMed
Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology. 2007;18:800–4. CrossRef
Rosales-Alexander JL, Salvatierra J, Llorca JM, C., González-Gay MA, Cantero-Hinojosa J, Raya-Álvarez E. Cardiovascular risk assessment in rheumatoid arthritis: impact of the EULAR recommendations on a national calibrated score risk index. Clin Exp Rheumatol 2014, Epub ahead.
del Rincon I, Williams K, Stern M, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arth Rheum. 2001;44:2737–45. CrossRef
Solomon DH, Greenberg J, Curtis JR, Liu M, Farkouh ME, Tsao P, et al. Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: A Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheum. 2015;67(8):1995–2003. CrossRef
Solomon DH, Ayanian JZ, Yelin E, Shaykevich T, Brookhart MA, Katz JN. Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey. Arthritis Care Res (Hoboken). 2012;64(5):184–9. CrossRef
De Vera M, Choi H, Abrahamowicz M, Kopec J, Lacaille D. Impact of statin discontinuation on mortality in patients with rheumatoid arthritis: a population-based study. Arthritis Care Res (Hoboken). 2012;64(6):809–16. CrossRef
Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, Epub ahead.
- Management of hyperlipidemia among patients with rheumatoid arthritis in the primary care setting
Joshua F. Baker
Nehal N. Mehta
Catherine T. Williams
- BioMed Central
Neu im Fachgebiet Orthopädie und Unfallchirurgie
Mail Icon II